Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology

Hum Gene Ther. 1992 Jun;3(3):319-38. doi: 10.1089/hum.1992.3.3-319.
No abstract available

MeSH terms

  • Adolescent
  • Adult
  • Bone Marrow Transplantation*
  • CD8 Antigens
  • Clinical Protocols
  • Combined Modality Therapy
  • HIV Seropositivity / complications
  • HIV Seropositivity / drug therapy
  • HIV Seropositivity / therapy*
  • Humans
  • Immunotherapy, Adoptive*
  • Lymphoma, AIDS-Related / etiology
  • Lymphoma, AIDS-Related / surgery
  • Lymphoma, AIDS-Related / therapy*
  • Middle Aged
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Cytotoxic / transplantation*
  • Zidovudine / therapeutic use

Substances

  • CD8 Antigens
  • Zidovudine